【STTT】复旦大学最新科研：发掘癌症免疫治疗潜在策略
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q3.itc.cn/q_70/images03/20240530/e2cf3e5e4f66412287a9ae2fac3d9d5f.jpeg" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">作者：Rainbow</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">导读：</strong>常规1型树突状细胞（cDC1）是抗肿瘤免疫中必不可少的抗原呈递DC亚群。<span style="color: black;">控制</span>B细胞淋巴瘤9和B细胞淋巴瘤9样（BCL9/BCL9L）可<span style="color: black;">控制</span>肿瘤生长并<span style="color: black;">加强</span>对癌症的免疫反应。然而，致癌性BCL9/BCL9L<span style="color: black;">是不是</span>损害肿瘤中的抗原呈递仍不完全清楚。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">5月29日，复旦大学朱棣、王明伟共同通讯在期刊《Signal Transduction and Targeted Therapy》上在线<span style="color: black;">发布</span>题为“Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration”的<span style="color: black;">科研</span>论文，<strong style="color: blue;"><span style="color: black;">科研</span>数据<span style="color: black;">发掘</span>，靶向BCL9/BCL9L在cDC1调节的肿瘤衍生抗原呈递中起<span style="color: black;">重要</span><span style="color: black;">功效</span>，随后在cDC1触发的CD8<span style="color: black;">+</span>T细胞激活和肿瘤浸润中起<span style="color: black;">重要</span><span style="color: black;">功效</span>，<span style="color: black;">形成</span>最佳抗肿瘤免疫所需的正反馈回路。<span style="color: black;">要紧</span>的是，<span style="color: black;">科研</span>为<span style="color: black;">控制</span>Wnt/β-catenin信号传导<span style="color: black;">供给</span>了一种极好的机制，<span style="color: black;">经过</span>促进抗原呈递来促进CD8<span style="color: black;">+</span>T细胞介导的抗肿瘤反应。<span style="color: black;">因此呢</span>，<span style="color: black;">科研</span>结果为<span style="color: black;">加强</span>BCL9/BCL9L高表达肿瘤对癌症免疫治疗的易感性<span style="color: black;">供给</span>了<span style="color: black;">有些</span>见解。</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q9.itc.cn/q_70/images03/20240530/1956ec7a634e4dbb945cfe55a07e566b.jpeg" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.nature.com/articles/s41392-024-01838-9</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">科研</span>背景</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">01</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">抗原呈递<span style="color: black;">针对</span>抗肿瘤反应是必不可少的。为了<span style="color: black;">导致</span>有效的抗肿瘤CD8+T细胞反应，抗原呈递<span style="color: black;">必要</span>在两个<span style="color: black;">重点</span>事件中成功：<span style="color: black;">首要</span>，肿瘤抗原被抗原呈递细胞（APC）<span style="color: black;">捕捉</span>，加工成肽片段，并呈递在<span style="color: black;">拥有</span><span style="color: black;">重点</span>组织相容性复合物I类（MHC-I）或人类白细胞抗原I类（HLA-I）的APC上，以<span style="color: black;">诱发</span>CD8+T细胞。其次，活化的CD8+T细胞识别APC直接呈递的肿瘤抗原，<span style="color: black;">而后</span>杀死肿瘤细胞。传统的1型树突状细胞（cDC1）被认为是将肿瘤抗原呈递到MHC-I上以<span style="color: black;">诱发</span>CD8+T细胞的优越DC亚群。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">先前的<span style="color: black;">科研</span><span style="color: black;">显示</span>，BATF3−/−<span style="color: black;">选取</span>性缺乏cDC1的小鼠表现出交叉呈递缺陷并损害抗肿瘤免疫。在人类癌症中，越来越多证据表明，瘤内cDC1与癌症免疫治疗的预后和反应改善<span style="color: black;">相关</span>。然而，DC<span style="color: black;">一般</span>是功能失调的、不成熟的，<span style="color: black;">乃至</span>是免疫<span style="color: black;">控制</span>的，缺乏在肿瘤微环境（TME）内交叉<span style="color: black;">起步</span>的抗原呈递能力。<span style="color: black;">另外</span>，cDC1很少见，<span style="color: black;">由于</span>TME<span style="color: black;">经过</span><span style="color: black;">各样</span>机制将cDC1从肿瘤中排除。<strong style="color: blue;"><span style="color: black;">因此呢</span>，旨在<span style="color: black;">加强</span>抗原呈递的<span style="color: black;">办法</span>，<span style="color: black;">包含</span><span style="color: black;">增多</span>cDC1活化和肿瘤浸润，<span style="color: black;">能够</span>促进抗肿瘤免疫并改善癌症免疫治疗。</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">科研</span><span style="color: black;">发掘</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">02</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">在<span style="color: black;">科研</span>中，<span style="color: black;">科研</span>人员报告了BCL9 / BCL9L的<span style="color: black;">控制</span>或耗竭<span style="color: black;">明显</span><span style="color: black;">控制</span>了肿瘤生长并<span style="color: black;">加强</span>了抗肿瘤反应。有趣的是，靶向BCL9/BCL9L以<span style="color: black;">加强</span>cDC1的抗原呈递能力并促进cDC1和CD8 +T细胞浸润到肿瘤中，这强调了这种<span style="color: black;">办法</span>在<span style="color: black;">加强</span>cDC1介导的抗肿瘤免疫方面的关键<span style="color: black;">功效</span>。旨在改善抗原呈递的疗法可能受益于与BCL9<span style="color: black;">控制</span>剂的联合<span style="color: black;">运用</span>。<strong style="color: blue;">靶向BCL9/BCL9L调节cDC1功能并直接协调最佳抗肿瘤免疫所需的正反馈回路<span style="color: black;">能够</span><span style="color: black;">做为</span>对抗免疫<span style="color: black;">控制</span>和<span style="color: black;">加强</span>癌症免疫治疗的潜在策略。</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="//q2.itc.cn/q_70/images03/20240530/1df1a3c16d544e7c9ef0083277802d2a.jpeg" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">靶向BCL9/BCL9L使肿瘤对免疫<span style="color: black;">检测</span>点阻断疗法<span style="color: black;">敏锐</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">科研</span>结论</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">03</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">综上所述，<strong style="color: blue;"><span style="color: black;">科研</span>数据<span style="color: black;">发掘</span>，靶向BCL9/BCL9L在cDC1调节的肿瘤衍生抗原呈递中起<span style="color: black;">重要</span><span style="color: black;">功效</span>，随后在cDC1触发的CD8<span style="color: black;">+</span>T细胞激活和肿瘤浸润中起<span style="color: black;">重要</span><span style="color: black;">功效</span>，<span style="color: black;">形成</span>最佳抗肿瘤免疫所需的正反馈回路。<span style="color: black;">要紧</span>的是，<span style="color: black;">科研</span>为<span style="color: black;">控制</span>Wnt/β-catenin信号传导<span style="color: black;">供给</span>了一种极好的机制，<span style="color: black;">经过</span>促进抗原呈递来促进CD8<span style="color: black;">+</span>T细胞介导的抗肿瘤反应。<span style="color: black;">因此呢</span>，<span style="color: black;">科研</span>结果为<span style="color: black;">加强</span>BCL9/BCL9L高表达肿瘤对癌症免疫治疗的易感性<span style="color: black;">供给</span>了<span style="color: black;">有些</span>见解。</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参考资料：</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">https://www.nature.com/articles/s41392-024-01838-9</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">注：本文旨在介绍医学<span style="color: black;">科研</span><span style="color: black;">发展</span>，<span style="color: black;">不可</span><span style="color: black;">做为</span>治疗<span style="color: black;">方法</span>参考。如需<span style="color: black;">得到</span>健康<span style="color: black;">指点</span>，请至正规医院就诊。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">热门·直播/活动</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"> “板凳”（第三个回帖的人） 对于这个问题，我有不同的看法...
页:
[1]